Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma

Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma

ObjectiveBesides breast and gastric cancer, HER2 amplification/mutation are also found in lung adenocarcinoma (LUAD). However, the correlation between HER2 variations and the phenotype of immunogenicity and tumor immune microenvironment (TIME) in LUAD compared with breast and gastric cancer has yet...

Full description

Bibliographic Details
Main Authors:	Qinyang Wang, Ziyang Mao, Wenyuan Li, Shumei Wang, Lei Wang, Lin Chen, Zhe Yang, Xiaolan Fu, Panpan Jiang, Yixue Bai, Longwen Xu, Shirong Zhang, Yuzhu Hou, Xiaohui Jia, Lili Jiang, Mengjie Liu, Guanjun Zhang, Yina Jiang, Hui Guo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Immunology
Subjects:	HER2 amplification lung adenocarcinoma immunogenicity tumor immune microenvironment
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.1042072/full

Similar Items

Targeting HER2 expression in cancer: New drugs and new indications
by: Semir Vranić, et al.
Published: (2021-02-01)

EFFECT OF TARGETED INHIBITION OF Myc ON IMMUNOGENICITY OF LEWIS LUNG CARCINOMA WHOLE-CELL VACCINE IN MICE
by: ZHANG Xueming, WANG Hui, QIAN Dongmeng, WANG Bin
Published: (2023-08-01)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
by: Laura Morsberger, et al.
Published: (2022-11-01)

Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver in situ hybridization in lung adenocarcinoma
by: Miladinović Mirjana, et al.
Published: (2021-10-01)

HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
by: Marina Popović, et al.
Published: (2023-05-01)

Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses
by: Insu Jeon, et al.
Published: (2020-07-01)

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)
by: Guangjian Yang, et al.
Published: (2022-08-01)

Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in HER2-amplification recurrent mucinous ovarian carcinoma
by: Xiangming Fang, et al.
Published: (2022-12-01)

<i>HER2</i> Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review
by: Burak Gonullu, et al.
Published: (2023-02-01)

HER2 Amplification in p53-Mutated Endometrial Carcinomas
by: Ambre Balestra, et al.
Published: (2023-02-01)

ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition
by: Afsaneh Barzi, et al.
Published: (2024-02-01)

A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers
by: Fnu Amisha, et al.
Published: (2023-05-01)

The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD‐L1 expression
by: Xiaoqian Jing, et al.
Published: (2023-12-01)

Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
by: Ayumu Yoshikawa, et al.
Published: (2022-12-01)

Challenges and future of HER2-positive gastric cancer therapy
by: Chenzhe Ma, et al.
Published: (2023-01-01)

Targeted therapy for multiple gene mutations in multiple metastases of advanced gastric cancer: a case report
by: Xin Zhang, et al.
Published: (2023-12-01)

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies
by: Natalie F. Uy, et al.
Published: (2022-08-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

ELISA-like QDB method to meet the emerging need of Her2 assessment for breast cancer patients
by: Guohua Yu, et al.
Published: (2023-03-01)

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma
by: Paula González-Alonso, et al.
Published: (2015-08-01)

Influences of obesity on the immunogenicity of Hepatitis B vaccine
by: Fang Liu, et al.
Published: (2017-05-01)

HER2-Positive Lacrimal Sac Squamous Cell Carcinoma in a 57-Year-Old Man
by: Nikolay Grachev, et al.
Published: (2024-01-01)

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
by: Yanjie Han, et al.
Published: (2023-04-01)

Bacterial Immunogenicity Prediction by Machine Learning Methods
by: Ivan Dimitrov, et al.
Published: (2020-11-01)

Experience with olaparib in a patient with luminal HER2-positive metastatic breast cancer
by: L. V. Bolotina, et al.
Published: (2022-06-01)

Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation
by: Kellsye P. Fabian, et al.
Published: (2022-11-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-05-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
by: Yuxin Mu, et al.
Published: (2023-12-01)

Ultrasensitive assay of HER1, HER2, and heregulin-α in whole blood
by: Raluca-Ioana Stefan-van Staden, et al.
Published: (2022-12-01)

Neratinib for HER2-positive breast cancer with an overlooked option
by: Liting Guo, et al.
Published: (2023-10-01)

Development and Validation of an Ultrasound-Based Radiomics Nomogram for Identifying HER2 Status in Patients with Breast Carcinoma
by: Yinghong Guo, et al.
Published: (2022-12-01)

Comparison of the pCR Rate and DFS Among Breast Cancer Patients with Different Hormone Receptor and HER2 Statuses
by: Jin Y, et al.
Published: (2023-05-01)

Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition
by: Dmitrii Kamashev, et al.
Published: (2022-08-01)

Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer
by: Huizi Lei, et al.
Published: (2023-06-01)

INTRATUMORAL AMPLIFICATION HETEROGENEITY IN HER2/neu-POSITIVE BREAST CANCER MOLECULAR-GENETIC SUBTYPES
by: L. N. Vashchenko, et al.
Published: (2019-11-01)

Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells
by: Marie Colombe Agahozo, et al.
Published: (2021-08-01)

Addition of Trastuzumab Deruxtecan to Selpercatinib in a Patient With RET Fusion-Driven NSCLC and an Acquired HER2 Amplification: Case Report
by: Chetan V. Vakkalagadda, MD, et al.
Published: (2023-12-01)

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers
by: Elizabeth Rubin, et al.
Published: (2024-01-01)